Sugi Predict

Sugi Predict / Compounds / SCHEMBL2083261

SCHEMBL2083261

SCHEMBL2083261

CCO/C=C(\C(=O)OCC)C(=O)c1ccc(Cl)nc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.39
▸ KMT2A Q03164 6/20 0.39
▸ NPSR1 Q6W5P4 4/20 0.39
▸ MAPT P10636 8/20 0.37
▸ LMNA P02545 4/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ S1PR4 O95977 1/20 0.37
▸ S1PR1 P21453 1/20 0.37
▸ KDM4E B2RXH2 3/20 0.36
▸ DHODH Q02127 3/20 0.36
▸ GAA P10253 3/20 0.36
▸ TSHR P16473 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ PLIN1 O60240 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ PLIN5 Q00G26 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29980565 1.00 MEN1 (0.39) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL2083262 1.00 MEN1 (0.39) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL29457319 1.00 MEN1 (0.39) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL21174020 0.88 SLC6A12 (0.33) MEN1KMT2AKDM4ETSHRSMN1; SMN2
SCHEMBL18949530 0.86 MEN1 (0.41) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL2083264 0.85 MEN1 (0.40) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL2086904 0.83 MEN1 (0.38) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL2086908 0.83 MEN1 (0.38) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL19987096 0.82 NPSR1 (0.36) MEN1KMT2ANPSR1MAPTLMNA
SCHEMBL29457333 0.82 NPSR1 (0.36) MEN1KMT2ANPSR1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115554294-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2023-01-03 — — CN disclosed
CN-115477649-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-12-16 — — CN disclosed
CN-115429798-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-12-06 — — CN disclosed
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2022-10-18 — — US disclosed
CN-109689656-B 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-10-04 — — CN disclosed
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2022-03-24 — — US disclosed
EP-3512849-B1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE BAYER AG (DE) 2021-06-23 — — EP disclosed
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-02-23 — — US disclosed
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-02-23 — — US disclosed
EP-3307741-B1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR Bayer Pharma AG (DE) 2020-10-28 — — EP disclosed
US-20120245198-A1 COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER SUNESIS PHARMACEUTICALS INC. 2012-09-27 — — US disclosed
US-8124773-B2 1,8-naphthyridine compounds for the treatment of cancer SUNESIS PHARMACEUTICALS, INC. (US) 2012-02-28 — — US disclosed
EP-2354138-A1 Compounds and compositions for treatment of cancer Sunesis Pharmaceuticals, Inc. (US) 2011-08-10 — — EP disclosed
US-7902226-B2 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 — — US disclosed
US-20100029708-A1 COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER SUNESIS PHARMACEUTICALS, INC. 2010-02-04 — — US disclosed
EP-1336611-B1 DEHALOGENO COMPOUNDS DAIICHI SEIYAKU CO (JP) 2007-09-05 — — EP disclosed
US-20070123560-A1 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. 2007-05-31 — — US disclosed
US-20040063754-A1 Dehalogeno compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 — — US disclosed
EP-1336611-A1 DEHALOGENO COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-08-20 — — EP disclosed
US-5457104-A Antibacterials BAYER AKTIENGESELLSCHAFT (DE) 1995-10-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063754-A1 Dehalogeno compounds DEK, PGLS, RPS27L MEN1 3821/4885KMT2A 2835/4885NPSR1 328/4885
US-20120245198-A1 COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER NTPCR, NNMT, NES MEN1 325/4885KMT2A 3277/4885NPSR1 558/4885
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF AADAC, GLS, NAT1 MEN1 3502/4885KMT2A 2845/4885NPSR1 1072/4885
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 MEN1 3502/4885KMT2A 2845/4885NPSR1 1072/4885
US-20100029708-A1 COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER NTPCR, NNMT, NES MEN1 325/4885KMT2A 3277/4885NPSR1 558/4885
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 MEN1 3502/4885KMT2A 2845/4885NPSR1 1072/4885
US-20070123560-A1 Dehalogeno-compounds DEK, RPS27L, POLL MEN1 4011/4885KMT2A 3591/4885NPSR1 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.